Minimal residual disease in solid tumors:an overview

作     者：Yarui Ma Jingbo Gan Yinlei Bai Dandan Cao Yuchen Jiao Yarui Ma;Jingbo Gan;Yinlei Bai;Dandan Cao;Yuchen Jiao

作者机构：State Key Laboratory of Molecular OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Genetron Health(Beijing)Co.Ltd.Beijing 102206China 

出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)

年 卷 期：2023年第17卷第4期

页      面：649-674页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by National Key R&D Program of China(Nos.2021YFC2500900 and 2021YFC2501004) the Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(CIFMS)(Nos.2021-1-I2M-018 and 2021-I2M-1-067) Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences(No.2022-RC310-08) 

主　　题：MRD solid tumor CTC ctDNA 

摘      要：Minimal residual disease(MRD)is termed as the small numbers of remnant tumor cells in a subset of patients with *** biopsy is increasingly used for the detection of MRD,illustrating the potential of MRD detection to provide more accurate management for cancer *** new techniques and algorithms have enhanced the performance of MRD detection,the approach is becoming more widely and routinely used to predict the prognosis and monitor the relapse of cancer *** fact,MRD detection has been shown to achieve better performance than imaging *** this basis,rigorous investigation of MRD detection as an integral method for guiding clinical treatment has made important *** review summarizes the development of MRD biomarkers,techniques,and strategies for the detection of cancer,and emphasizes the application of MRD detection in solid tumors,particularly for the guidance of clinical treatment.